에 대한 최신 뉴스 Zai Lab (NASDAQ:ZLAB) 주식

Zai Lab

Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. The pipeline of proprietary drug candidates of the company includes ZL-1218 (CCR8) Solid Tumors, ZL-1310 (DLL3 ADC) ES-SCLC Other NECs, ZL-6301 (ROR1 ADC) Solid Tumors, ZL 6201 (LRRC15 ADC) Solid Tumors.

Stuttgart,,Germany,-,08-24-2023:,Person,Holding,Cellphone,With,Website,Of

Equities

Mid Cap

News

Movers

AIFU

APLD

BPMC

CRWV

KYMR

NVCR

RIOT

RXRX

SEZL

ZLAB

어플라이드 디지털, 라이엇 플랫폼스 등 지난주 급등한 중형주 10종목 (6월 2일~6일)

Las,Vegas,,Usa,-,April,13,,2014:,Hertz,Car,Rental

BULL

CERT

MTSR

SBSW

VIST

허츠, 비스타 에너지 등 지난주 급등한 중형주 6종목 (4월 14~18일)

Zai Lab Limited - American Depositary Shares

Zai Lab Ltd

WIIM

JBIO

Jade Biosciences shares are trading higher after the company a detailed preclinical characterization of JADE101, its anti-A Proliferation-Inducing Ligand (APRIL) monoclonal antibody, in development for IgA nephropathy

Goldman Sachs analyst Leah Jordan downgrades Conagra Brands (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAG#NYSE">CAG</a>) from Neutral to Sell and lowers the price target from $26 to $21.

Downgrades

Price Target

Analyst Ratings

Goldman Sachs Downgrades Conagra Brands to Sell, Lowers Price Target to $21

Turtle Beach Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TBCH#NASDAQ">TBCH</a>, the "Company"))), a leading gaming accessories brand, today announced that its Board of Directors (the "Board") has approved the adoption of a limited duration stockholder rights plan (the "Rights Plan") and declared a dividend distribution of one right ("Right") for each outstanding share of common stock. The record date for such dividend distribution is June 23, 2025.
The adoption of the Rights Plan is intended to enable all stockholders to realize the full potential value of their investment in the Company and protect the Company and its stockholders from the actions of third parties that the Board determines are not in the best interests of the Company and its stockholders. In addition, the Rights Plan provides the Board with time to make informed, deliberate decisions that are in the best long-term interests of the Company and its stockholders. The Rights Plan will expire, without any further action being required to be taken by the Board, on June 9, 2026.
The Rights Plan is similar to stockholder rights plans adopted by other publicly-held companies. Under the Rights Plan, the Rights generally would become exercisable only if a person or group acquires beneficial ownership of 10% or more of the Company's common stock in a transaction not approved by the Board. In that situation, each holder of a Right (other than the acquiring person or group, whose Rights will become void and will not be exercisable) will be able to purchase, upon payment of the then-current exercise price, a number of shares of the Company's common stock having a market value of twice such price. In addition, if the Company is acquired in a merger or other business combination after an acquiring person acquires 10% or more of the Company's common stock, each holder of the Right would thereafter be able to purchase, upon payment of the then-current exercise price, a number of shares of common stock of the acquiring company having a market value of twice such price. The acquiring person or group would not be entitled to exercise these Rights.
The Rights Plan includes a qualifying offer clause, which provides stockholders with the potential ability to call a special meeting for purposes of exempting a pending offer that meets certain qualifying criteria.
The Rights Plan has not been adopted in response to any specific takeover bid or other proposal to acquire control of the Company and is not intended to deter offers that are fair and otherwise in the best interests of the Company and its stockholders.
Stockholders who currently beneficially own 10% or more of the Company's outstanding common stock will not trigger any penalties under the Rights Plan so long as they do not acquire beneficial ownership of any additional shares of common stock on a cumulative basis, subject to certain exceptions as described in the Rights Plan.

Management

TBCH

Turtle Beach Board Approves Limited Duration Stockholder Rights Plan To Protect Shareholder Value And Declares Dividend Of One Right Per Share, Effective June 23, 2025

<h3>Gainers</h3>
<table>
<thead>
<tr>
<th>Symbol</th>
<th>Name</th>
<th align="right">Price</th>
<th align="right">Change ($)</th>
<th align="right">Change (%)</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLC#NYSE">XLC</a>)</td>
<td>The Communication Services Select Sector SPDR Fund</td>
<td align="right">104.25</td>
<td align="right">0.54</td>
<td align="right">0.52</td>
<td>3.0K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLE#NYSE">XLE</a>)</td>
<td>SPDR Select Sector Fund - Energy Select Sector</td>
<td align="right">83.69</td>
<td align="right">0.28</td>
<td align="right">0.33</td>
<td>44.8K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLK#NYSE">XLK</a>)</td>
<td>SPDR Select Sector Fund - Technology</td>
<td align="right">239.10</td>
<td align="right">0.74</td>
<td align="right">0.31</td>
<td>105.6K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLF#NYSE">XLF</a>)</td>
<td>SPDR Select Sector Fund - Financial</td>
<td align="right">51.41</td>
<td align="right">0.13</td>
<td align="right">0.25</td>
<td>26.3K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLI#NYSE">XLI</a>)</td>
<td>SPDR Select Sector Fund - Industrial</td>
<td align="right">145.23</td>
<td align="right">0.30</td>
<td align="right">0.20</td>
<td>4.8K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLU#NYSE">XLU</a>)</td>
<td>SPDR Select Sector Fund - Utilities</td>
<td align="right">81.34</td>
<td align="right">0.15</td>
<td align="right">0.18</td>
<td>2.4K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLB#NYSE">XLB</a>)</td>
<td>Materials Select Sector SPDR</td>
<td align="right">87.89</td>
<td align="right">0.11</td>
<td align="right">0.12</td>
<td>611</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLV#NYSE">XLV</a>)</td>
<td>SPDR Select Sector Fund - Health Care</td>
<td align="right">134.51</td>
<td align="right">0.13</td>
<td align="right">0.09</td>
<td>4.0K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLRE#NYSE">XLRE</a>)</td>
<td>Real Estate Select Sector SPDR Fund (The)</td>
<td align="right">41.91</td>
<td align="right">0.03</td>
<td align="right">0.07</td>
<td>4.9K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLP#NYSE">XLP</a>)</td>
<td>SPDR Select Sector Fund - Consumer Staples</td>
<td align="right">81.70</td>
<td align="right">0.01</td>
<td align="right">0.01</td>
<td>4.0K</td>
</tr>
</tbody>
</table>
<h3>Losers</h3>
<table>
<thead>
<tr>
<th>Symbol</th>
<th>Name</th>
<th align="right">Price</th>
<th align="right">Change ($)</th>
<th align="right">Change (%)</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLY#NYSE">XLY</a>)</td>
<td>SPDR Select Sector Fund - Consumer Discretionary</td>
<td align="right">211.91</td>
<td align="right">-0.26</td>
<td align="right">-0.13</td>
<td>3.8K</td>
</tr>
</tbody>
</table>
<a href="https://pro.benzinga.com/?utm_source=insights">Pulled from Benzinga Pro data</a> this sector movers alerts can help traders understand macro-level market trends. Traders often look for sector movers to provide high-level analysis on which sectors are over- or under-performing to make better investing decisions on exchange traded funds (ETFs) or individual tickers in those sectors. 
To read more about sector movers, <a href="https://www.benzinga.com/movers">click here</a>.

Sector ETFs

Pre-Market Outlook

ETFs

XLRE

Select Sector SPDR-Consumer Discretionary

Leading And Lagging Sectors For June 9, 2025

Singular focus on Bittensor (TAO), the leading AI token by adoption and market capitalization
James Altucher to lead TAO token strategy initiatives
Planned initial acquisition of $10 million in TAO equates to over two times the Company's&nbsp; current market capitalization; total acquisition target of $100 million
NEW YORK, June 9, 2025 /PRNewswire/ -- Synaptogenix, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNPX#NASDAQ">SNPX</a>) ("Synaptogenix" or the "Company") today announced its launch of a differentiated cryptocurrency treasury strategy focused exclusively on the artificial intelligence (AI) crypto token "TAO," which is currently the top AI token by market capitalization and adoption. Well-known cryptocurrency and AI expert James Altucher will lead a TAO-based revenue generation strategy targeting staking yield and token appreciation.
Synaptogenix plans to acquire $10 million in TAO tokens initially, which amounts to over two times the Company's current market valuation. The Company's strategy is targeted to acquire $100 million of TAO tokens. The initial acquisition will be funded by the Company's significant cash reserves and well-capitalized balance sheet.

SNPX

Synaptogenix Launches $100M AI Token Treasury Strategy Focused On Bittensor (TAO) With $10M Initial Acquisition Led by Crypto Expert James Altucher

Goldman Sachs analyst James Yaro downgrades General Mills (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GIS#NYSE">GIS</a>) from Buy to Neutral and lowers the price target from $68 to $58.

Goldman Sachs Downgrades General Mills to Neutral, Lowers Price Target to $58

Grant Cardone,&nbsp;the CEO of Cardone Capital,&nbsp;accused Federal Reserve Chairman&nbsp;Jerome Powell&nbsp;of causing the country&#8217;s &#8220;housing crisis.&#8221; Cardone argued that Powell&#8217;s policies have significantly impacted the housing market.
What Happened: Cardone, in an <a href="https://www.foxbusiness.com/media/real-estate-tycoon-rips-fed-chair-powell-doing-more-damage-housing-market">interview </a>during &#8220;Mornings with Maria&#8221; with Fox Business on Monday, stated that Powell&#8217;s decisions have had a detrimental effect on the middle class and the housing market. He specifically pointed to the high interest rates, which he believes are preventing people from purchasing homes.
Cardone also criticized Powell for maintaining high interest rates despite a drop in inflation. He suggested that lower rates could stimulate market activity and subsequently lower home prices due to increased supply.
&#8220;He [Jerome Powell] has done more damage to the middle class and to&nbsp;housing in this country&nbsp;than any other single Fed or any decision that has ever been made out of Washington, D.C.,&#8221; Cardone stated.&nbsp;
He also credited the decline in inflation to President Donald Trump's "enthusiasm, optimism, and speculation of opening up the marketplace."
SEE ALSO:&nbsp;<a href="https://benzinga.com/markets/macro-economic-events/25/06/45831613/collapse-in-immigration-poses-a-bigger-economic-threat-than-trumps-tariffs-warns-deutsche-bank-negative-supply-shock-is-not-good-news-for-a-currency" target="_blank" rel="noreferrer noopener">&#8216;Collapse In Immigration&#8217; Poses A Bigger Economic Threat Than Trump&#8217;s Tariffs, Warns Deutsche Bank: &#8216;Negative Supply Shock Is Not Good News For A Currency&#8217; &#8211; Benzinga</a>
Why It Matters: The real estate tycoon&#8217;s comments come in the wake of the Federal Open Market Committee&#8217;s decision to maintain the benchmark interest rates at 4.25% to 4.5% following its May meeting.
Cardone&#8217;s criticism of Powell&#8217;s policies echoes sentiments expressed by other industry leaders. Earlier in May,&nbsp;Federal Housing Finance Agency (FHFA) Director William Pulte <a href="https://www.benzinga.com/25/05/45637583/federal-housing-finance-chief-calls-on-powell-to-lower-interest-rates-the-housing-market-would-be-in-much-better-shape">urged&nbsp;Powell </a>to lower interest rates, stating that it would significantly improve the housing market.
However, economists are divided on the issue. Following a strong May jobs report, some believe that the&nbsp;Federal Reserve <a href="https://www.benzinga.com/markets/macro-economic-events/25/06/45832125/as-trump-flames-powell-for-holding-back-on-rate-cuts-economists-divided-on-feds-approach">should maintain</a> its current stance, while others argue that the central bank should start cutting interest rates.
Meanwhile, President Trump, who has been a vocal advocate for interest rate reductions,&nbsp;<a href="https://www.benzinga.com/markets/economic-data/25/06/45818251/trump-cheers-strong-jobs-data-renews-attack-on-feds-powell-rates-should-be-much-lower">renewed his attack</a> on Powell&nbsp;after the release of the strong May employment report, asserting that rates &#8220;should be much lower.&#8221;
<ul class="wp-block-list">
<li>READ MORE:&nbsp;<a href="https://benzinga.com/news/politics/25/06/45831188/gavin-newsom-to-sue-trump-administration-over-national-guard-deployment-dares-border-czar-homan-to-" target="_blank" rel="noreferrer noopener">Gavin Newsom To Sue Trump Administration Over National Guard Deployment, Dares Border Czar Homan To &#8216;Arrest&#8217; Him</a></li>
</ul>
Image via Shutterstock
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Markets

Grant Cardone Says Jerome Powell Has Done 'More Damage' To American Middle Class Than 'Any Other Single Fed,' Blames Fed For 'Housing Crisis'

Enables Upexi to build a community and foster relationships with Webull's 24 million registered users
Upexi, Inc. (NASDAQ:<a href="https://www.benzinga.com/stock/UPXI#NASDAQ">UPXI</a>), a brand owner specializing in the development, manufacturing, and distribution of consumer products with diversification into the cryptocurrency space, today announced joining the Webull Corporate Connect Service (CCS) platform to increase engagement and transparency with investors.
Upexi's portal on the Webull Corporate Connect Service provides a direct communication channel for shareholders and potential investors, reinforcing the Company's commitment to engaging with the investment community. Through Webull, Upexi will share timely updates, including company news, earnings reports, presentations, and other key announcements.

UPXI

Upexi Joins Webull Corporate Connect Service Platform To Increase Engagement And Transparency With Investors

<a href="https://www.bloomberg.com/news/articles/2025-06-09/bofa-sees-saudis-embarking-on-long-but-shallow-oil-price-war?taid=6846daffc3bbb300014af67b&amp;utm_campaign=trueanthem&amp;utm_content=business&amp;utm_medium=social&amp;utm_source=twitter" title="https://www.bloomberg.com/news/articles/2025-06-09/bofa-sees-saudis-embarking-on-long-but-shallow-oil-price-war?taid=6846daffc3bbb300014af67b&amp;utm_campaign=trueanthem&amp;utm_content=business&amp;utm_medium=social&amp;utm_source=twitter">https://www.bloomberg.com/news/articles/2025-06-09/bofa-sees-saudis-embarking-on-long-but-shallow-oil-price-war?taid=6846daffc3bbb300014af67b&amp;utm_campaign=trueanthem&amp;utm_content=business&amp;utm_medium=social&amp;utm_source=twitter</a>

Macro Economic Events

Global

Economics

'BofA Sees Saudis Embarking on Long But Shallow Oil-Price War' - Bloomberg News

Graham shares are trading higher after the company reported better-than-expected Q4 financial results.

Acquisition Will Expand Covius' Title Presence and Technology Platform Integrations
DENVER, June 9, 2025 /PRNewswire/ -- Covius Services, LLC, a leading provider of technology-enabled solutions to the financial services industry, announced today it has signed a definitive agreement to acquire Title365 Holding Co.,&nbsp;a national provider of title insurance and settlement services with deep integrations across industry platforms, from Blend Labs, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BLND#NYSE">BLND</a>), a leading digital origination platform for banks, credit unions and mortgage lenders.
The transaction is subject to certain required third-party consents and regulatory approvals. It is expected to close in the coming months.
Title365 is a national title insurance and settlement services company licensed in 43 states, serving top-10 lenders and servicers as well as capital market participants and home equity originators. Title365's full range of products cover first and second mortgage origination services as well as default title. The company is also broadly integrated with leading loan origination and industry platforms.
In addition to servicing its own client base, Title365 will continue to partner with Blend to provide integrated title and closing services for Blend customers. Kirby Hulbert, President of Title365, and his team will be joining Covius' Settlement Services team.

Asset Sales

BLND

Covius To Acquire Title365 From Blend Labs; Deal Expected to Close in Coming Months; No Financial Terms Disclosed

As of June 9, 2025, three stocks in the financial sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
The RSI is a momentum indicator, which compares a stock&#8217;s strength on days when prices go up to its strength on days when prices go down. When compared to a stock&#8217;s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered overbought when the <a href="https://www.benzinga.com/topic/rsi">RSI is above 70</a>, according to <a href="https://pro.benzinga.com/">Benzinga Pro</a>. 
Here's the latest list of major overbought players in this sector.
<h3 class="wp-block-heading">Shinhan Financial Group Co Ltd (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SHG#NYSE">SHG</a>)</h3>
<ul class="wp-block-list">
<li>On April 23, Shinhan Financial Group filed its FY2024 Form 20-F to the SEC. The company's stock jumped around 19% over the past month and has a 52-week high of $46.05.</li>
<li>RSI Value: 79.6&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</li>
<li>SHG Price Action: Shares of Shinhan Financial closed at $42.90 on Friday.</li>
<li>Edge Stock Ratings: 84.77 Momentum score. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/quote/SHG"><img loading="lazy" decoding="async" width="408" height="182" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/09090201/image-113.png" alt="" class="wp-image-943165" style="width:282px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/09090201/image-113.png 408w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/09090201/image-113-300x134.png 300w" sizes="(max-width: 408px) 100vw, 408px" /></a></figure>
<h3 class="wp-block-heading">mF International Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MFI#NASDAQ">MFI</a>)</h3>
<ul class="wp-block-list">
<li>On June 4, mF International named Haoyu Wang as CEO, replacing Chi Weng Tam. The company's stock gained around 214% over the past month and <a href="https://www.benzinga.com/quote/MFI">has a 52-week high</a> of $3.13.</li>
<li>RSI Value: 72</li>
<li>MFI Price Action: Shares of mF International closed at $2.17 on Friday.</li>
</ul>
<h3 class="wp-block-heading">Great Elm Group Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GEG#NASDAQ">GEG</a>)</h3>
<ul class="wp-block-list">
<li>On May 7, Great Elm Group reported a third-quarter loss of 17 cents per share, versus a year-ago loss of 10 cents per share. Jason Reese, Chief Executive Officer of the Company stated, &#8220;We achieved a solid fiscal third quarter 2025, continuing our positive momentum by expanding our assets under management and maintaining performance across our credit and real estate businesses. Notably, GECC delivered record total investment income in the first calendar quarter of 2025 and continues to drive significant growth in our fee-paying assets under management. GECC is also well positioned to pay meaningful incentive fees to GEG in the coming quarters.&#8221; The company's stock gained around 15% over the past month and has a <a href="https://www.benzinga.com/quote/GEG">52-week high</a> of $2.20.</li>
<li>RSI Value: 78.9</li>
<li>GEG Price Action: Shares of Great Elm Group closed at $2.18 on Friday.</li>
</ul>
Curious about other BZ Edge Rankings? Click here to discover <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-2#:~:text=Turn%20Market%20Chaos,when%20markets%20rebound">how similar stocks measure up</a>. 
Read This Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/25/06/45811726/cramer-says-hes-not-going-to-really-want-to-do-a-lot-of-china-right-now">Cramer Says He&#8217;s &#8216;Not Going To Really Want To Do A Lot Of China Right Now&#8217;</a> </li>
</ul>
Photo via Shutterstock

Short Ideas

Top 3 Financial Stocks That May Collapse In June

Goldman Sachs analyst James Yaro initiates coverage on Etoro Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ETOR#NASDAQ">ETOR</a>) with a Buy rating and announces Price Target of $76.

Initiation

ETOR

Goldman Sachs Initiates Coverage On Etoro Group with Buy Rating, Announces Price Target of $76

Editor&#8217;s Note: The EPS estimate for Q1 has been corrected
Genesco Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GCO#NYSE">GCO</a>), on Wednesday, reported <a target="_blank" href="https://www.benzinga.com/pressreleases/25/06/b45766387/genesco-inc-reports-fiscal-2026-first-quarter-results" rel="noreferrer noopener">mixed first-quarter 2026 results</a> and reaffirmed fiscal 2026 EPS guidance.
The company reported an adjusted loss per share of $2.05, beating the street view of $2.09 loss. Quarterly sales of $473.973 million (increased 4% year over year) were above the analyst consensus estimate of $465.30 million.
Net sales were driven by a 5% increase at Journeys, 4% at Schuh, and 7% at Genesco Brands, partly offset by a 3% decline at Johnston &amp; Murphy.
Also Read:<a target="_blank" href="https://www.benzinga.com/markets/large-cap/25/06/45770679/alibaba-jd-see-sales-soar-in-618-festival-apple-and-xiaomi-emerge-as-top-selling-brands" rel="noreferrer noopener"> Alibaba, JD See Sales Soar In 618 Festival, Apple And Xiaomi Emerge As Top Selling Brands</a>
Comparable sales rose 5%, with stores up 5% and e-commerce up 7%. On a constant currency basis, Schuh sales rose 1%.
The first quarter&#8217;s gross margin fell to 46.7% from 47.6% a year ago, mainly due to brand mix shifts at Journeys and Schuh, promotions at Schuh, and lower margins from product liquidations at Genesco Brands.
Genesco reported a GAAP operating loss of $28.1 million, or 5.9% of sales, down from $32.1 million, or 7%, a year ago. On an adjusted basis, the loss narrowed to $27.9 million from $30.0 million, with the operating margin improving to a loss of 5.9% of sales from a loss of 6.5% in the first quarter last year.
As of May 3, 2025, Genesco held $21.7 million in cash, up from $19.2 million a year earlier. Total debt rose to $121 million from $59.4 million, mainly due to a 15% inventory increase to support higher demand at Journeys.
Genesco repurchased 604,531 shares for $12.6 million, or $20.79 per share, during the quarter. Under its expanded buyback program, announced in June 2023, it has $29.8 million remaining.
In the first quarter, capital expenditures totaled $19 million, mainly for retail stores and other projects. The company opened four new stores and closed 26, ending the quarter with 1,256 stores. This represents a 5% decrease from 1,321 stores at the end of the first quarter last year. Overall square footage also decreased by 3% year-over-year.
Mimi E. Vaughn, Genesco&#8217;s Board Chair, president, and CEO, said, &#8220;While an already choppy consumer environment has become more pronounced recently from the increased uncertainty due to tariffs, our diversified sourcing and mitigation actions position us well to manage the current tariff impact. In addition, our strong strategic positioning and track record of evolving our businesses in the face of market disruptions are giving us confidence in successfully navigating the current environment.&#8221;
&#8220;Today, we are reiterating our full-year adjusted EPS guidance of $1.30 to $1.70, incorporating the impact of current tariffs. Although there is ongoing external market uncertainty, we know our businesses are strong, and we are making investments in product, stores, and marketing across all brands to drive growth,&#8221; commented Sandra Harris, Genesco&#8217;s Senior VP of Finance and CFO.
For fiscal 2026, Genesco reaffirmed its expectation of adjusted diluted EPS between $1.30 and $1.70 versus the consensus estimate of $1.47, factoring in current tariffs.
Total sales are now projected to rise 1%–2%, up from prior guidance of flat to 1%, due to favorable foreign exchange. Comparable sales range outlook narrowed to up 2% to 3% versus the prior range of up 2% to 4%, with no additional share buybacks assumed and a 29% tax rate.
Price Action: GCO shares are trading higher by 1.39% to $22.66 at last check Wednesday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/earnings/25/06/45768682/dollar-tree-q1-same-store-sales-jump-5-4-warns-of-near-term-profit-drop-on-tariff-pressure-transition-costs" target="_blank" rel="noreferrer noopener">Dollar Tree Q1 Same-Store Sales Jump 5.4%, Warns Of Near-Term Profit Drop On Tariff Pressure, Transition Costs</a></li>
</ul>
Photo by JHVEPhoto via Shutterstock

Earnings

Guidance

Genesco Acknowledges 'More Pronounced' Tariff Impact, Stands By Guidance (CORRECTED)

Production continues for U.S. Navy's most advanced maritime radar
ANDOVER, Mass., June 9, 2025 /PRNewswire/ --&nbsp;Raytheon, an RTX (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RTX#NYSE">RTX</a>) business, was awarded a $646 million contract to continue producing <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4444448-1&amp;h=1868559343&amp;u=https%3A%2F%2Fwww.rtx.com%2Fraytheon%2Fwhat-we-do%2Fsea%2Fspy6-radars&amp;a=AN%2FSPY-6(V)+radars">AN/SPY-6(V) radars</a>&nbsp;for the U.S. Navy. This is the fourth option exercised from the <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4444448-1&amp;h=3316422061&amp;u=https%3A%2F%2Fwww.rtx.com%2Fraytheon%2Fnews%2F2022%2F03%2F16%2Fspy6-hps-contract&amp;a=March+2022+hardware%2C+production+and+sustainment+contract">March 2022 hardware, production and sustainment contract</a>&nbsp;that is valued up to $3 billion over five years.
Under this contract, the U.S. Navy will receive four additional radars, increasing the total amount of radars under contract for procurement to 42.
Majority of the work under this contract will take place at the Andover facility through 2028.

RTX's Raytheon Awarded $646M Contract To Continue Producing AN/SPY-6(V) Radars For U.S. Navy

Productive and collaborative discussion on proposed pathway by the company to bring crofelemer to approval for cancer therapy-related diarrhea (CTD) in patients with metastatic breast cancer receiving selected targeted therapies
The currently estimated US metastatic breast cancer population would qualify as an orphan population, which aligns with company's core focus on orphan diseases
Company plans to promptly pursue authorization to initiate expanded access program for patients with breast cancer who may not be eligible for a potential pivotal treatment trial with crofelemer in patients with metastatic breast cancer
SAN FRANCISCO, CA / <a href="https://www.accessnewswire.com/">ACCESS Newswire</a> / June 9, 2025 / <a href="https://pr.report/ba6y">Jaguar Health, Inc.</a><a href="https://pr.report/ba7e">(NASDAQ:</a><a href="https://www.benzinga.com/stock/JAGX#NASDAQ">JAGX</a>) (Jaguar) family company Napo Pharmaceuticals (Napo) today provided a recap on the company's assessment of the in-person Type C Meeting on May 28, 2025 with the Division of Gastroenterology of the U.S. Food and Drug Administration (FDA) to discuss the statistically significant responder analysis results for adult patients with breast cancer in Napo's recently conducted Phase 3 <a href="https://pr.report/ba6z">OnTarget</a> trial.

Biotech

General

JAGX

Jaguar Health's Napo Pharma Advances Crofelemer For Cancer Therapy-Related Diarrhea Following FDA Type C Meeting

Synaptogenix Names James Altucher To Lead Digital Asset Treasury Strategy

ESGL Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ESGL#NASDAQ">ESGL</a>), a leading provider of sustainable waste management and circular chemical solutions, today announced that its Chairman and Chief Executive Officer, Mr. Quek Leng Chuang, has acquired 336,134 ordinary shares of ESGL at an average purchase price of $2.25 per share. The shares were acquired through private transactions. This increases Mr. Quek's total ownership in the company to approximately 8.2%.

ESGL

ESGL Holdings Chairman And CEO, Quek Leng Chuang, Purchases 336,134 Ordinary Shares Of ESGL At Average Purchase Price Of $2.25/Shr

<a href="https://www.globenewswire.com/Tracker?data=Ou9kpYQseMcOTKihNNuPbZdbdUfYNyXJYPkg3pQ3KLwvRZ9k2ky7RIhZaSLxWcu0SRZ9435v_vidgmuJsbcVFQ==">Cemtrex Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CETX#NASDAQ">CETX</a>, CETXP))), an advanced security technology and industrial services company, today announced that it has received a notification letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") notifying the Company that it has regained compliance with the minimum stockholders' equity requirement under Nasdaq Listing Rule 5550(b)(1). The Company's security will continue to be listed and traded on The Nasdaq Stock Market.
Cemtrex previously received a notification letter from the Nasdaq Listing Qualifications Department on February 21, 2025, notifying the Company that, because the stockholders' equity for the Company was below the minimum required for continued listing on the Nasdaq Capital Market under Nasdaq Listing Rule 5550(b)(1).
Based on the Company's Form 10-Q filed on May 15, 2025, evidencing stockholders' equity of $6,403,022, Nasdaq has determined that the Company complies with the Minimum Stockholder's Equity Requirement and this matter is now closed.

CETX

Cemtrex Regains Compliance With Nasdaq Requirements

- Crown Electrokinetics Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRKN#NASDAQ">CRKN</a>) ("Crown" or the "Company"), a leader in optical and fiber infrastructure solutions, today announced that it has entered into a definitive Agreement and Plan of Merger (the "Merger Agreement") with Crown EK Acquisition LLC ("Parent") and Crown EK Merger Sub Corp. ("Purchaser"), a wholly owned subsidiary of Parent.
Parent is controlled by Douglas Croxall, the Company's Chairman and Chief Executive Officer. Under the terms of the Merger Agreement, Purchaser will commence a tender offer to acquire all outstanding shares of Crown's common stock for a cash purchase price of&nbsp;$3.15 per share, subject to the terms and conditions of the Merger Agreement.
The proposed transaction has been unanimously approved by a special committee (the "Special Committee") comprised of independent directors of Crown's board of directors and is intended to result in Crown becoming a wholly owned subsidiary of Parent. The Special Committee received a fairness opinion from an independent financial advisor and determined the transaction is fair to, and in the best interests of, Crown's unaffiliated public stockholders.

CRKN

Crown Electrokinetics Enters Merger Agreement To Be Acquired For $3.15/Share In All-Cash Tender Offer Led By CEO-Controlled Entity

Press Releases

Zai Lab to Present New Data from Internally Developed, Next-Generation Oncology Candidates at AACR 2025 Annual Meeting

Zai Lab to Announce First Quarter 2025 Financial Results and Recent Corporate Updates on May 8, 2025

Zai Lab Announces Acceptance of Supplemental New Drug Application for Repotrectinib for Patients with NTRK-Positive Solid Tumors

Zai Lab to Present Data from Phase 1 Trial of DLL3-Targeted Antibody-Drug Conjugate (ADC) ZL-1310 at 2025 ASCO Annual Meeting

Zai Lab Presents Data Highlighting Potential of Internally Developed, Next-Generation Oncology Therapies at AACR 2025

Zai Lab Announces First Quarter 2025 Financial Results and Recent Corporate Updates

Zai Lab Receives U.S. FDA Fast Track Designation for ZL-1310, a DLL3-Targeted Antibody-Drug Conjugate, for Treatment of Extensive-Stage Small Cell Lung Cancer

Zai Lab Announces Participation in Investor Conferences in June 2025

Zai Lab and Novocure Announce Results From the Phase 3 PANOVA-3 Trial of Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer to be Presented at 2025 ASCO Annual Meeting

Zai Lab Presents Positive Phase 1 Data for ZL-1310, a DLL3-Targeted ADC, Demonstrating Robust Anti-Tumor Activity and Safety in Patients with Extensive-Stage Small Cell Lung Cancer at 2025 ASCO Annual Meeting

ACADIA Pharmaceuticals Inc. - Common Stock

ACADIA Pharmaceuticals

Arcellx

ADMA Biologics

Akero Therapeutics

Alkermes

Alvotech

Catalyst Pharmaceuticals, Inc. - Common Stock

Catalyst Pharmaceuticals

Cytokinetics, Incorporated - Common Stock

Cytokinetics

Grifols, S.A. - American Depositary Shares

Grifols

Ionis Pharmaceuticals, Inc. - Common Stock

Ionis Pharmaceuticals

Krystal Biotech

Madrigal Pharmaceuticals, Inc. - Common Stock

Madrigal Pharmaceuticals

Nuvalent

Vaxcyte

PTC Therapeutics

Protagonist Therapeutics, Inc. - Common Stock

Protagonist Therapeutics

Ultragenyx Pharmaceutical Inc. - Common Stock

Ultragenyx Pharmaceutical

Avidity Biosciences

Rhythm Pharmaceuticals, Inc. - Common Stock

Rhythm Pharmaceuticals

Soleno Therapeutics

Sarepta Therapeutics, Inc. - Common Stock

Sarepta Therapeutics

Scholar Rock Holding Corporation - Common Stock

Scholar Rock Holding

SpringWorks Therapeutics, Inc. - common stock

SpringWorks Therapeutics

Telix Pharmaceuticals Limited - American Depositary Shares

Telix Pharmaceuticals

Viking Therapeutics

JP Morgan

Scotiabank

B of A Securities

Citigroup

Morgan Stanley

지난주 가장 좋은 성과를 거든 중형주 10종목은 다음과 같다.
<ol class="wp-block-list">
<li>어플라이드 디지털(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APLD#NASDAQ">APLD</a>) 주가는 AI 하이퍼스케일러 코어위브(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRWV#NASDAQ">CRWV</a>)와 장기 <a href="https://www.benzinga.com//node/45817409" target="_blank" rel="noreferrer noopener">인프라 계약</a> 발표 후 102.93% 상승했다.</li>
<li>키메라 테라퓨틱스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KYMR#NASDAQ">KYMR</a>) 주가는 60.66% 급등했다. 회사는 KT-621의 건강한 자원자 1상 연구의 임상 결과를 공개했다. 모건스탠리와 B라일리 증권은 각각 투자의견을 비중 확대와 매수로 상향 조정했으며, <a href="https://www.benzinga.com/quote/kymr/analyst-ratings" target="_blank" rel="noreferrer noopener">여러 애널리스트들이 목표주가를 상향 조정했다.</a></li>
<li>퍼스트 마제스틱 실버(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AG#NYSE">AG</a>) 주가는 지난 주 34.04% 증가했다. 목요일 은 가격이 온스당 35.60달러를 넘어섰으며 2012년 이후 처음 있는 일이다. 금 강세론자 피터 쉬프는 <a href="https://www.benzinga.com//node/45792880" target="_blank" rel="noreferrer noopener">지금이 급등의 시작이라고 말했다</a>.</li>
<li>AIFU(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AIFU#NASDAQ">AIFU</a>) 주가는 31.78% 상승했다.</li>
<li>리커전 파마슈티컬스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RXRX#NASDAQ">RXRX</a>) 주가는 MIT와의 파트너십으로 <a href="https://www.benzinga.com//node/45814396" target="_blank" rel="noreferrer noopener">Boltz-2 출시 발표</a> 후 31.34% 상승했다.</li>
<li>클리블랜드 클리프스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLF#NYSE">CLF</a>) 주가는 미국 대통령 도널드 트럼프가 <a href="https://www.benzinga.com//node/45724684" target="_blank" rel="noreferrer noopener">철강 관세를 두 배로 늘리겠다고 발표한 후</a> 30.36% 상승했다.</li>
<li>자이랩(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZLAB#NASDAQ">ZLAB</a>) 주가는 26.44% 상승했다. 회사와 노보큐어 리미티드(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVCR#NASDAQ">NVCR</a>)는 토요일에 췌장암에 대한 종양 치료 분야 (TTFields) 요법의 <a href="https://www.benzinga.com//node/45730717" target="_blank" rel="noreferrer noopener">3상 PANOVA-3 시험의 추가 데이터를 공개했다</a>.</li>
<li>블루프린트 메디슨스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BPMC#NASDAQ">BPMC</a>) 주가는 사노피 SA(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNY#NASDAQ">SNY</a>)가 <a href="https://www.benzinga.com//node/45719179" target="_blank" rel="noreferrer noopener">블루프린트를 95억 달러에 인수할 것이라고 발표한 후</a> 26.15% 상승했다.</li>
<li>세즐(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SEZL#NASDAQ">SEZL</a>) 주가는 지난 주 23.78% 상승했다.</li>
<li>라이엇 플랫폼스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIOT#NASDAQ">RIOT</a>) 주가는 22.06% 상승했다. 회사는 5월에 514 비트코인을 채굴했으며, 이는 전월 대비 11% 증가하고 <a href="https://www.benzinga.com//node/45752589" target="_blank" rel="noreferrer noopener">전년 대비 139% 증가한 수치다.</a></li>
</ol>
사진 출처: T. 슈나이더 via Shutterstock
Benzinga Pro의 독점 뉴스 및 도구로 수익률을 높이세요.
독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

지난주 가장 좋은 성과를 낸 중형주는 다음과 같다.
<ol>
<li>위불(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BULL#NASDAQ">BULL</a>) 주식은 <a href="https://www.benzinga.com//node/44876727" target="_blank" rel="noreferrer noopener">지난주 초 나스닥에 상장</a>되었고 주가는 119.05% 상승했다.</li>
<li>허츠 글로벌(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HTZ#NASDAQ">HTZ</a>) 주가는 99.03% 급등했다. 이는 빌 애크먼의 퍼싱 스퀘어 캐피털 매니지먼트가 수정된 13F를 제출하며 1,271만 주의 허츠 주식을 매수했다고 밝혔기 때문이다. 매입된 주식은 허츠 지분의 <a href="https://www.benzinga.com//node/44853443" target="_blank" rel="noreferrer noopener">약 4.1%을 의미한다.</a></li>
<li>멧세라(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MTSR#NASDAQ">MTSR</a>) 주가는 49.62% 상승했다. 이는 화이자(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>)가 <a href="https://www.benzinga.com//node/44790653" target="_blank" rel="noreferrer noopener">다누글리프론(danuglipron) </a>개발을 중단했다는 소식에 따른 것이다.</li>
<li>비스타 에너지(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VIST#NYSE">VIST</a>) 주가는 35.52% 급등했다. 이는 회사가 9억 달러의 현금, 3억 달러의 후불, <a href="https://www.benzinga.com//node/44848713" target="_blank" rel="noopener">약 730만 ADS 단위</a>로 구성된 혼합 거래를 통해 페트로나스 E&amp;P 아르헨티나(Petronas E&amp;P Argentina)를 인수했다고 발표한 이후다.</li>
<li>시바니 스틸워터(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SBSW#NYSE">SBSW</a>) 주가는 27.76% 상승했다. 이는 아마도 금 가격이 3,300달러를 넘어 사상 최고치로 나아가는 랠리와 관련이 있다.</li>
<li>방코 마크로(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMA#NYSE">BMA</a>) 주가는 27.71% 상승했다.</li>
</ol>
사진 제공: Shutterstock
Benzinga Pro의 독점 뉴스 및 도구로 수익률을 높이세요.
독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

Comments

Zai Lab

뉴스

에 대한 최신 뉴스 Zai Lab (NASDAQ:ZLAB) 주식

월요일, 6월 09, 2025

일요일, 4월 20, 2025

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌